Indegene's ₹1,842-cr IPO to open on 6 May: Check date, issue price, allotment quota and other details
Upstox
2 min read • Updated: April 29, 2024, 3:37 PM
Summary
Indegene IPO: The offer will comprise of two components — a fresh issue of ₹760 crore, and an offer-for-sale (OFS) of 2.39 crore shares, amounting to ₹1,088.9 crore. This takes the overall issue size to about ₹1,848.9 crore.
Indegene, a Bengaluru-based biotech and medical devices company, is scheduled to launch its initial public offering (IPO) next month. In the documents related to issue submitted so far, the firm has shared key details, such as the issue dates, price, and allotment of quotas.
The IPO will open on May 6 and close on May 8. The tentative issue price is ₹455 per share, with the face value set at ₹2 per share.
The offer will comprise of two components — a fresh issue of ₹760 crore, and an offer-for-sale (OFS) of 2.39 crore shares, amounting to ₹1,088.9 crore. This takes the overall issue size to about ₹1,848.9 crore.
Post the IPO, Indegene will be listed on both the main bourses — the National Stock Exchange of India (NSE) and the BSE.
The retail investors' quota in the IPO has been fixed at 35%, whereas qualified institutional buyers (QIB) have been alloted 50%. The remaining 15% has been earmarked for non-institutional investors (NII).
Indegene's financial performance
In fiscal year ended March 2023 (FY23), Indegene had reported a revenue of ₹2,306 crore, whereas its expenses in the same period stood at ₹2,001 crore, IPO Central reported, citing the company's data. The net income in the same period came in at ₹266 crore, higher as compared to ₹166 crore in FY22.
For the nine-month period ending December 2023, Indegene reported a revenue of ₹1,916.6 crore, and an expense of ₹1,644.6 crore. The net income stood at ₹241.9 crore.
As per the data compiled by the web portal, the adjusted earnings before interest, taxes, depreciation and ammortisation (EBITDA) margin stood at 19.7% in FY23, marginally higher as against 18.8% in FY22.